Amazon Crosses $3 Trillion as Iran De-Escalation Sparks Broad Rally, Oil Sinks 6%

Merger Arbitrage

Merger arbitrage is a strategy built around trading the gap between a target company's current stock price and the price an acquirer has agreed to pay for it. Once a deal is announced, the target's stock typically jumps toward - but not all the way to - the offer price. That remaining gap is called the spread, and it exists because the deal hasn't closed yet: there's still time between announcement and completion during which something could go wrong. The size of the spread is really a market-implied probability estimate. A narrow spread means the market thinks the deal is very likely to close on the announced terms and close soon; a wide spread means the market sees meaningful risk - regulatory objection, financing falling through, a shareholder vote failing, or a rival bidder emerging. Today's Atkore deal is a clean example of a low-risk situation: Prysmian signed a definitive, all-cash agreement at $95 a share, a firm number with a firm structure, so Atkore's stock should trade tight to that $95 figure with only a small discount reflecting the time value of money and modest closing risk. Compare that to AstraZeneca and Bristol Myers Squibb, where reports describe only early-stage talks with no confirmed agreement, no announced price, and no certainty a deal happens at all. There's no defined spread to trade yet, because there are no defined terms - AstraZeneca's roughly 7% drop reflects the market pricing in the risks and dilution of a potential mega-merger (and the antitrust scrutiny likely given both companies' overlapping oncology and cardiovascular franchises), not arbitrage math around a locked-in price. Professional merger-arb funds specialize in exactly this distinction: they get paid for correctly judging which deals are Atkore-like (high certainty, thin spread, modest but reliable return) versus which are still speculative stories that may never become tradeable deals at all.